Loading…
Loading…
BIOS (BioPlus Acquisition Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
BIOS does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIOS and 80,000+ other tickers.
See exactly how BIOS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIOS and 80,000+ other tickers.
Currently, BioPlus Acquisition Corp. possesses no major active business operations. Its express mandate is to pursue and complete a strategic combination, which may take the form of a merger, share exchange, asset purchase, stock acquisition, reorganization, or similar transaction. This targeted consolidation is specifically aimed at one or more entities within the vibrant life sciences industry. The corporation was formally established in 2021 and maintains its principal executive offices in New York, New York.
COMPUTEX 2026: MiTAC Advances Diversified AI Infrastructure Through Strategic Ecosystem Partnerships PR Newswire
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the “Business Combination Agreement”), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering (“Public Shares”).
- Transaction values Avertix at an enterprise value of $195 million - Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, Friday, December 3, 2021, under the ticker symbol “BIOSU”. Each unit consists one of the Company's Class A ordinary shares and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one of the Company's Class A ordinary shares at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “BIOS” and “BIOSW,” respectively.
BANNOCKBURN, Ill., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today that it has completed the reverse 1-for-4 stock split of its shares of common stock, as previously disclosed in the Company’s filings with the Securities and Exchange Commission. As of market open on February 3, 2020, the Company’s common stock, which was previously listed on the Nasdaq Capital Market under the symbol “BIOS”, will begin trading on a split-adjusted basis on the Nasdaq Global Select Market under the ticker symbol “OPCH” and will be assigned a new CUSIP number (68404L 201).